Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.39 USD
Change Today +0.12 / 1.45%
Volume 1.3M
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$8.30
Previous Close
$8.27
Day High
$8.53
Day Low
$8.19
52 Week High
06/24/14 - $13.78
52 Week Low
12/23/14 - $5.34
Market Cap
722.4M
Average Volume 10 Days
1.6M
EPS TTM
$-0.66
Shares Outstanding
86.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

307 Employees
Last Reported Date: 08/28/14
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $544.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $245.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $432.4K
Executive Vice President of Distinguished Res...
Total Annual Compensation: $377.2K
Compensation as of Fiscal Year 2014.

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Revises Earnings Guidance for the Year Ending June 30, 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported a net loss of $21.6 million, or $0.25 per basic and diluted share, compared to a net loss of $37.5 million, or $0.44 per basic and diluted share, for the same quarter last year. Revenues for the quarter were $11.4 million, compared to $6.9 million for the same period last year. The current period includes a $5.1 million of revenue from license and milestone fees, just principally a $5 million cash milestone payment earned from Novartis. Loss from operations was $21.2 million compared with $37.4 million a year ago. For the nine months, the company's total revenues were $72.9 million compared with $54.2 million a year ago. Loss from operations was $29.4 million compared with $45.0 million a year ago. Net loss was $30.3 million or $0.35 per basic and diluted share compared with $44.9 million or $0.53 per basic and diluted share a year ago. Cash used in operations was $27.4 million in the period and capital expenditures were $4.5 million. The company has updated its guidance for its fiscal year ending June 30, 2015. The company's guidance for its net loss is unchanged, and expected to be between $60 million and $65 million. Expected revenues are now projected to be between $85 million and $95 million, compared with previous guidance of between $100 million and $105 million, due to changes in the expected timing of partner milestone events. The company's guidance for cash used in operations and capital expenditures remains unchanged from that issued on January 2015. These are projected to be between $55 million and $60 million and between $7 million and $9 million, respectively.

ImmunoGen, Inc. Appoints Anna Berkenblit as Vice President and Chief Medical Officer

ImmunoGen, Inc. announced the appointment of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. Dr. Berkenblit reports to Dr. Charles Morris, EVP and Chief Development Officer and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. Dr. Berkenblit has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine.

Takeda Pharmaceutical Company Limited Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

Takeda Pharmaceutical Company Limited and ImmunoGen, Inc. announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. The agreement also provides Takeda with the option to take a license for a third target for an additional upfront fee. ImmunoGen will receive $20 million upfront and for each target is eligible to receive milestone payments potentially totaling up to $210 million plus royalties on the commercial net sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this agreement. Takeda signed an agreement with ImmunoGen through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $8.39 USD +0.12

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.85 EUR -0.05
Abzena PLC 82.00 GBp -1.00
BioInvent International AB kr1.91 SEK -0.01
Kyowa Hakko Kirin Co Ltd ¥1,755 JPY -1.00
MorphoSys AG €64.35 EUR -0.399
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.